ArticleFuture virology2010
Establishment and maintenance of HIV latency: model systems and opportunities for intervention.
Article in Future virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Brain viral reservoir seeding and neurological metabolic dysregulation in early-life immunodeficiency virus infection.Brain pathology (Zurich, Switzerland) · 2026Article
- Intragenic transcription from defective HIV proviruses triggers interferon responses in myeloid cells.Journal of virology · 2026Article
- Intragenic Transcription from Defective HIV Proviruses Triggers Interferon Responses in Myeloid Cells.bioRxiv : the preprint server for biology · 2026Article
- Viral reservoir seeding and neurological metabolic dysregulation in early-life immunodeficiency virus infection.Research square · 2025Article
- FUBP3 enhances HIV-1 transcriptional activity and regulates immune response pathways in T cells.Molecular therapy. Nucleic acids · 2025Article
- Strategies for HIV-1 suppression through key genes and cell therapy.Frontiers in medicine · 2023Review
- Selective miRNA Modulation Fails to Activate HIV Replication in In Vitro Latency Models.Molecular therapy. Nucleic acids · 2019Article
- Establishment of latent HIV-1 reservoirs: what do we really know?Journal of virus eradication · 2019Article
- Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.Virology · 2018Article
- Humanized Mouse Models for Human Immunodeficiency Virus Infection.Annual review of virology · 2017Review
- Stelleralides D-J and Anti-HIV Daphnane Diterpenes from Stellera chamaejasme.Journal of natural products · 2015Article
- Studies of retroviral infection in humanized mice.Virology · 2015Review
- Experimental Approaches for Eliminating Latent HIV.Forum on immunopathological diseases and therapeutics · 2015Article
- Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery.ACS nano · 2014Article
- HIV/AIDS eradication.Bioorganic & medicinal chemistry letters · 2013Review
- Targeting IκB proteins for HIV latency activation: the role of individual IκB and NF-κB proteins.Journal of virology · 2013Article
- New generation humanized mice for virus research: comparative aspects and future prospects.Virology · 2013Review
- Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.Nature chemistry · 2012Article
- HIV latency in the humanized BLT mouse.Journal of virology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
HAART has succeeded in reducing morbidity and mortality rates in patients infected with HIV. However, a small amount of replication-competent HIV can persist during HAART, allowing the virus to re-emerge if therapy is ceased. One significant source of this persistent virus is a pool of long-lived, latently infected CD4(+) T cells. This article outlines what is known about how this reservoir is established and maintained, and describes the model systems that have provided insights into the molecular mechanisms governing HIV latency. The therapeutic approaches for eliminating latent cells that have been attempted are also discussed, including how improvements in understanding of these persistent HIV reservoirs are being used to develop enhanced methods for their depletion.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.